Cancer research
Researchers at First Affiliated Hospital have made a significant breakthrough in understanding the correlation between single-nucleotide polymorphisms (SNPs) of the Epidermal growth factor receptor (EGFR) gene and the susceptibility and survival prognosis of lung cancer patients. The study, published in Frontiers in Genetics, analyzed the EGFR gene's rs2227983,
Cancer research
Recent research from Wuhan University has shed light on the role of Galectin-1 (Gal-1) in regulating tumor progression, particularly in the context of lung cancer. The study revealed that high expression of Gal-1 in various cancers was inversely correlated with the overall survival of patients. Furthermore, it was discovered that
Cancer research
Research conducted in Northeast Italy has provided valuable insights into the diagnosis and management of prostate cancer (PCa) in patients aged 75 years and older. The study, conducted by the Gruppo Uro-Oncologico del Nord-Est (GUONE), involved 104 physicians from various specialties and aimed to assess current clinical practices and experiences
Cancer research
Research has revealed that patients with breast cancer detected through routine screening mammography experience improved clinical outcomes compared to those whose breast cancer is symptom-detected. A study published in Radiology: Imaging Cancer, a journal of the Radiological Society of North America (RSNA), discovered that patients with screening-detected breast cancer had
Cancer research
Researchers from the Chinese People's Liberation Army (PLA) General Hospital have made a significant discovery in cancer diagnostics, developing an enzyme-linked immunosorbent assay (ELISA) that uses nanotechnology to detect cancer biomarkers with unprecedented sensitivity. This novel approach has the potential to revolutionize cancer diagnosis and point-of-care testing. According
Cancer research
A recent study published in The Prostate has investigated the association between thromboembolic events (TE) and castration-resistant prostate cancer (CRPC) patients receiving oral androgen receptor pathway inhibitors (ARPi) compared to those undergoing chemotherapy. The research used the Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database from 2012 to 2016,
Cancer research
British scientists have used artificial intelligence (AI) to identify which men with high-risk prostate cancer could most benefit from a hormone treatment that is currently denied by the NHS in England. The study found that one in four men could have their risk of death halved if given the treatment,
Cancer research
Researchers say that an AI-powered test could help doctors determine which patients with advanced prostate cancer will benefit most from a life-extending treatment that is currently not approved for use in England. The study, led by The Institute of Cancer Research, London, and University College London (UCL), used images of
Cancer research
Researchers at the University of Illinois have presented fresh data on oncology - genital tract cancer, revealing that human papillomavirus (HPV)-related lower genital cancers pose a significant health burden, with approximately 45,000 new cases diagnosed annually. Current effective treatment modalities include chemoradiotherapy, systemic chemotherapy, and immune checkpoint inhibitors
Cancer research
Research from Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital shed light on the relationship between BIN1 expression and CD8+ T cell infiltration in non-small cell lung cancer (NSCLC). The study discovered that BIN1 expression is downregulated in NSCLC tumor tissues, associated with advanced disease progression and
Cancer research
Researchers from the Cancer Hospital in Beijing, People's Republic of China, have made a significant discovery in the field of lung cancer. By analyzing ferroptosis-related genes (FRGs) in small cell lung cancer (SCLC), they have identified three distinct subtypes: S1, S2, and S3. These subtypes have been linked
Cancer research
Research published in the Journal for ImmunoTherapy of Cancer has identified early predictive markers for primary refractory disease in patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab, a programmed cell death ligand 1 (PD-L1) inhibitor. The study, conducted by researchers at AdventHealth Cancer Institute, aimed to identify patients who
